Literature DB >> 16306156

Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification.

M Simon1, J Boström, P Koch, J Schramm.   

Abstract

OBJECTIVE: To document and critically analyse the impact of the revised WHO 2000 histological classification for meningiomas on postoperative radiotherapy/radiosurgery indications and MRI follow up protocols.
METHODS: The current (2000) WHO classification was used to grade 57 meningiomas treated surgically at one institution. These had been reviewed previously in 1999. All German neurosurgical departments carrying out intracranial microsurgery were asked to detail their guidelines for radiation therapy and follow up for meningiomas of different WHO grades.
RESULTS: Use of the current criteria downgraded seven of 15 atypical meningiomas (WHO grade II, MII) to grade I (MI), and four of six anaplastic tumours (WHO grade III, MIII) to grade II. Indications for radiotherapy/radiosurgery and MRI follow up protocols varied substantially with the histological grade and between institutions--for example, after an incomplete resection, radiotherapy/radiosurgery recommendations differed between MI and MII in 30 of 58 units (52%), and between MII and MIII in 34 of 56 units (61%).
CONCLUSIONS: Correlative studies combining treatment and outcome data with a standardised histopathological analysis are warranted to define properly the indications for radiotherapy/radiosurgery and follow up protocols after surgery for meningiomas of different histological grades. The use of changing grading paradigms during recent years renders decision making based on local and published experience difficult. The relatively large number of meningiomas classified as atypical/WHO grade II in current practice would argue against an uncritically aggressive approach to these tumours.

Entities:  

Mesh:

Year:  2005        PMID: 16306156      PMCID: PMC2077452          DOI: 10.1136/jnnp.2005.077974

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  33 in total

1.  Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients.

Authors:  S L Stafford; B E Pollock; R L Foote; M J Link; D A Gorman; P J Schomberg; J A Leavitt
Journal:  Neurosurgery       Date:  2001-11       Impact factor: 4.654

2.  Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.

Authors:  M Simon; T W Park; S Leuenroth; V H Hans; T Löning; J Schramm
Journal:  J Neurosurg       Date:  2000-05       Impact factor: 5.115

Review 3.  Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases.

Authors:  H W Jung; H Yoo; S H Paek; K S Choi
Journal:  Neurosurgery       Date:  2000-03       Impact factor: 4.654

4.  High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results.

Authors:  J Debus; M Wuendrich; A Pirzkall; A Hoess; W Schlegel; I Zuna; R Engenhart-Cabillic; M Wannenmacher
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

5.  Natural history of elderly patients with asymptomatic meningiomas.

Authors:  M Niiro; K Yatsushiro; K Nakamura; Y Kawahara; J Kuratsu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-01       Impact factor: 10.154

6.  Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.

Authors:  L Palma; P Celli; C Franco; L Cervoni; G Cantore
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

Review 7.  Radiotherapy for atypical or malignant intracranial meningioma.

Authors:  M F Milosevic; P J Frost; N J Laperriere; C S Wong; W J Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

8.  The natural history of incidental meningiomas.

Authors:  Makoto Nakamura; Florian Roser; Julia Michel; Cornelius Jacobs; Madjid Samii
Journal:  Neurosurgery       Date:  2003-07       Impact factor: 4.654

9.  Fractionated radiation therapy in the treatment of intracranial meningiomas: local control, functional efficacy, and tolerance in 91 patients.

Authors:  J P Maire; M Caudry; J Guérin; D Célérier; F San Galli; N Causse; R Trouette; M Dautheribes
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-09-30       Impact factor: 7.038

10.  Meningioma: analysis of recurrence and progression following neurosurgical resection.

Authors:  R O Mirimanoff; D E Dosoretz; R M Linggood; R G Ojemann; R L Martuza
Journal:  J Neurosurg       Date:  1985-01       Impact factor: 5.115

View more
  16 in total

1.  Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma.

Authors:  Dorota Lubgan; Sandra Rutzner; Ulrike Lambrecht; Karl Rössler; Michael Buchfelder; Ilker Eyüpoglu; Rainer Fietkau; Sabine Semrau
Journal:  J Neurooncol       Date:  2017-06-30       Impact factor: 4.130

2.  NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.

Authors:  John W Rutland; Corey M Gill; Joshua Loewenstern; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Raj K Shrivastava; Mary Fowkes
Journal:  Cancer Immunol Immunother       Date:  2020-07-13       Impact factor: 6.968

Review 3.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

4.  Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011.

Authors:  Ryan L Lym; Quinn T Ostrom; Carol Kruchko; Marta Couce; Daniel J Brat; David N Louis; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2015-04-12       Impact factor: 4.130

5.  Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial.

Authors:  Stephanie E Combs; Lutz Edler; Iris Burkholder; Stefan Rieken; Daniel Habermehl; Oliver Jäkel; Thomas Haberer; Andreas Unterberg; Wolfgang Wick; Jürgen Debus; Renate Haselmann
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

6.  High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539.

Authors:  C Leland Rogers; Minhee Won; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; Shannon E Fogh; Emad Youssef; Nimisha Deb; Young Kwok; Clifford G Robinson; Hui-Kuo Shu; Barbara J Fisher; Valerie Panet-Raymond; William G McMillan; John F de Groot; Peixin Zhang; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-11-29       Impact factor: 7.038

Review 7.  Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review.

Authors:  Gurvinder Kaur; Eli T Sayegh; Andrew Larson; Orin Bloch; Michelle Madden; Matthew Z Sun; Igor J Barani; C David James; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2014-04-02       Impact factor: 12.300

8.  Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas.

Authors:  Naureen Keric; Darius Kalasauskas; Christian F Freyschlag; Jens Gempt; Martin Misch; Alicia Poplawski; Nicole Lange; Ali Ayyad; Claudius Thomé; Peter Vajkoczy; Bernhard Meyer; Florian Ringel
Journal:  J Neurooncol       Date:  2020-01-03       Impact factor: 4.130

9.  The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells.

Authors:  Liangjuan Fang; Daniel E Lowther; Matthew L Meizlish; Richard C E Anderson; Jeffrey N Bruce; Lesley Devine; Anita J Huttner; Steven H Kleinstein; Jae-Yun Lee; Joel N H Stern; Gur Yaari; Laura Lovato; Katharine M Cronk; Kevin C O'Connor
Journal:  Neuro Oncol       Date:  2013-08-26       Impact factor: 12.300

10.  Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma.

Authors:  Chenyang Wang; Tania B Kaprealian; John H Suh; Charlotte D Kubicky; Jeremy N Ciporen; Yiyi Chen; Jerry J Jaboin
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.